KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non-Current Assets (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Non-Current Assets for 16 consecutive years, with $26.9 billion as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Non-Current Assets rose 318.65% year-over-year to $26.9 billion, compared with a TTM value of $29.7 billion through Mar 2025, down 63.01%, and an annual FY2024 reading of $26.8 billion, down 13.62% over the prior year.
  • Non-Current Assets was $26.9 billion for Q1 2025 at Teva Pharmaceutical Industries, roughly flat from $26.8 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $36.6 billion in Q1 2021 and bottomed at -$12.3 billion in Q1 2024.
  • Average Non-Current Assets over 5 years is $27.0 billion, with a median of $32.0 billion recorded in 2022.
  • The sharpest move saw Non-Current Assets tumbled 138.48% in 2024, then soared 318.65% in 2025.
  • Year by year, Non-Current Assets stood at $35.1 billion in 2021, then dropped by 8.93% to $32.0 billion in 2022, then fell by 3.02% to $31.0 billion in 2023, then decreased by 13.62% to $26.8 billion in 2024, then grew by 0.42% to $26.9 billion in 2025.
  • Business Quant data shows Non-Current Assets for TEVA at $26.9 billion in Q1 2025, $26.8 billion in Q4 2024, and -$11.6 billion in Q2 2024.